Ctla 4 Inhibitor | List of Frontiers open access articles

Original Research

Published on 25 Aug 2022

Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma

in Cancer Immunity and Immunotherapy

Ying Zhang
Xiaolong Wu
Amit Sharma
Hans Weiher
Matthias Schmid
Glen Kristiansen
Ingo G. H. Schmidt-Wolf

Frontiers in Immunology

doi 10.3389/fimmu.2022.925633

4,720 views
8 citations

Systematic Review

Published on 22 Jul 2021

Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials

in Pharmacology of Anti-Cancer Drugs

Yang Ge
Huiyun Zhang
Nathaniel Weygant
Jiannan Yao

Frontiers in Pharmacology

doi 10.3389/fphar.2021.640099

3,198 views
5 citations

Systematic Review

Published on 06 Feb 2025

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis

in Cancer Immunity and Immunotherapy

Huimin Zhao
Shanshan Huang
Jianyu Wu
Yanlan Lu
Yue Zou
Haijian Zeng
Chunlan Li
Jin Wang
Xiaochen Zhang
Siliang Duan

Frontiers in Immunology

doi 10.3389/fimmu.2025.1515027

7,283 views
10 citations

Systematic Review

Published on 04 Feb 2019

Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis

in Cancer Immunity and Immunotherapy

Qiang Su
Emily C. Zhu
Jing-bo Wu
Teng Li
Yan-li Hou
Di-ya Wang
Zu-hua Gao

Frontiers in Immunology

doi 10.3389/fimmu.2019.00108

26,109 views
168 citations

Mini Review

Published on 21 Feb 2020

Immunotherapy in Malignant Pleural Mesothelioma

in Thoracic Oncology

Cornedine J. de Gooijer
Frank J. Borm
Arnaud Scherpereel
Paul Baas

Frontiers in Oncology

doi 10.3389/fonc.2020.00187

15,691 views
72 citations

Review

Published on 04 Oct 2023

Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer

in Breast Cancer

Hongsheng Zhang
Jintao Mi
Qi Xin
Weiwei Cao
Chunjiao Song
Naidan Zhang
Chengliang Yuan

Frontiers in Oncology

doi 10.3389/fonc.2023.1256360

7,771 views
19 citations

Review

Published on 06 Jun 2019

A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia

in Drugs Outcomes Research and Policies

Dan Liao
Mengyao Wang
Yi Liao
Jun Li
Ting Niu

Frontiers in Pharmacology

doi 10.3389/fphar.2019.00609

15,598 views
85 citations

Original Research

Published on 25 Aug 2020

Pilot Study of CT-Based Radiomics Model for Early Evaluation of Response to Immunotherapy in Patients With Metastatic Melanoma

in Cancer Imaging and Image-directed Interventions

Zhi-long Wang
Li-li Mao
Zhi-guo Zhou
Lu Si
Hai-tao Zhu
Xi Chen
Mei-juan Zhou
Ying-shi Sun
Jun Guo

Frontiers in Oncology

doi 10.3389/fonc.2020.01524

4,348 views
38 citations

Original Research

Published on 27 Oct 2025

Association between immune check point inhibitors and digestive system inflammatory adverse reactions: evidence from pharmacovigilance analysis and systematic review

in Drugs Outcomes Research and Policies

Ya Zou
Qinchuan Li
Lu Zhou
Yun Lu
Hua Wei
Yan Zhou
Shibo Lin
Xirui Guo
Shihao Yan
Hongju Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1684475

1,917 views

Systematic Review

Published on 10 Mar 2020

Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis

in Cancer Immunity and Immunotherapy

Wenhan Yang
Peng Men
Huimin Xue
Mingyan Jiang
Qiuhua Luo

Frontiers in Oncology

doi 10.3389/fonc.2020.00197

4,650 views
15 citations

Original Research

Published on 24 Nov 2025

Serum autoantibody profiles in cancer patients treated with immune checkpoint inhibitors: a cross-sectional study

in Cancer Immunity and Immunotherapy

Kun Chen
Bao’e Guo
Rufeng Liu
Juan Wang
Chen Zhang
Guobing Xu

Frontiers in Oncology

doi 10.3389/fonc.2025.1716014

1,153 views

Systematic Review

Published on 27 May 2021

Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis

in Cancer Immunity and Immunotherapy

Jiexuan Hu
Ruyue Tian
Yingjie Ma
Hongchao Zhen
Xiao Ma
Qiang Su
Bangwei Cao

Frontiers in Oncology

doi 10.3389/fonc.2021.645245

6,450 views
27 citations

Systematic Review

Published on 05 Feb 2024

A meta-analysis of the efficacy of programmed cell death 1/its ligand inhibitors plus cytotoxic T-lymphocyte-associated antigen 4 inhibitors in non-small cell lung cancer

in Pharmacology of Anti-Cancer Drugs

Li Lin
Lu Xiao
Lei Li
Chen Chen
Haorong Zhang
Changyan Yu
Lanfang Zhang
Anhua Wei
Wei Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1267763

2,522 views
3 citations

Articles

Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma

Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis

Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis

Immunotherapy in Malignant Pleural Mesothelioma

Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer

A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia

Pilot Study of CT-Based Radiomics Model for Early Evaluation of Response to Immunotherapy in Patients With Metastatic Melanoma

Association between immune check point inhibitors and digestive system inflammatory adverse reactions: evidence from pharmacovigilance analysis and systematic review

Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis

Serum autoantibody profiles in cancer patients treated with immune checkpoint inhibitors: a cross-sectional study

Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis

A meta-analysis of the efficacy of programmed cell death 1/its ligand inhibitors plus cytotoxic T-lymphocyte-associated antigen 4 inhibitors in non-small cell lung cancer